To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination

被引：94

作者：

Chiu, Nan-Chang ^{[1
,2
]}

Chi, Hsin ^{[1
,2
]}

Tu, Yu-Kang ^{[3
]}

Huang, Ya-Ning ^{[1
]}

Tai, Yu-Lin ^{[4
]}

Weng, Shun-Long ^{[5
]}

Chang, Lung ^{[2
,6
]}

Huang, Daniel Tsung-Ning ^{[1
,2
]}

Huang, Fu-Yuan ^{[1
]}

Lin, Chien-Yu ^{[2
,4
]}

机构：

[1] MacKay Childrens Hosp, Dept Pediat, Taipei, Taiwan

[2] MacKay Med Coll, Dept Med, New Taipei, Taiwan

[3] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Taipei, Taiwan

[4] Hsinchu MacKay Mem Hosp, Dept Pediat, Hsinchu, Taiwan

[5] Hsinchu MacKay Mem Hosp, Dept Obster & Genecol, Hsinchu, Taiwan

[6] Tamshui MacKay Mem Hosp, Dept Pediat, New Taipei, Taiwan

来源：

EXPERT REVIEW OF VACCINES | 2021年 / 20卷 / 10期

关键词：

COVID-19; Sars-COV-2; vaccination; heterologous; boost; chadox1; mRNA; EFFICACY; VACCINES;

D O I：

10.1080/14760584.2021.1971522

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction Coronavirus disease 2019 (COVID-19) has had an enormous impact worldwide, and vaccination is believed to be the method that will control the pandemic. Several types of vaccines developed using different platforms have been authorized, but the immunogenicity and reactogenicity of heterologous prime-boost vaccination with different vaccines remain largely unclear. Areas covered Electronic databases including PubMed, Embase, medRxiv, Research Square, and SSRN were searched to investigate the immunogenicity and reactogenicity associated with heterologous vaccination. As of 30 June 2021, four trials including 1,862 participants were identified. Heterologous administration of BNT162b2 (BNT) in ChAdOx1 (ChAd)-primed participants (ChAd/BNT) showed noninferior immunogenicity to homologous BNT administration (both prime and booster were BNT vaccines, BNT/BNT) with tolerable reactogenicity and higher T cell responses. Compared with homologous ChAdOX1 vaccination (ChAd/ChAd), heterologous ChAd/BNT was found to elicit higher immunogenicity (ChAd/BNT vs. ChAd/ChAd, antibody titer ratio: 9.2). Expert opinion Our systematic review found robust immunogenicity and tolerable reactogenicity of heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants. An additional benefit of stronger T cellular immunity was also observed. Heterologous vaccination is a reasonable and feasible strategy to combat COVID-19. Further studies are warranted to confirm the benefits and identify the optimal combinations, doses, and intervals.

引用

页码：1211 / 1220

页数：10

共 49 条

[41]

Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI [10.1056/NEJMoa2104840, 10.1056/NEJMoa2104882]

[42]

Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01115-6, 10.1016/S0140-6736(21)01158-2]

[43] Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice [J].

Spencer, Alexandra J. ;

McKay, Paul F. ;

Belij-Rammerstorfer, Sandra ;

Ulaszewska, Marta ;

Bissett, Cameron D. ;

Hu, Kai ;

Samnuan, Karnyart ;

Blakney, Anna K. ;

Wright, Daniel ;

Sharpe, Hannah R. ;

Gilbride, Ciaran ;

Truby, Adam ;

Allen, Elizabeth R. ;

Gilbert, Sarah C. ;

Shattock, Robin J. ;

Lambe, Teresa .

NATURE COMMUNICATIONS, 2021, 12 (01)

[44] mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection [J].

Stamatatos, Leonidas ;

Czartoski, Julie ;

Wan, Yu-Hsin ;

Homad, Leah J. ;

Rubin, Vanessa ;

Glantz, Hayley ;

Neradilek, Moni ;

Seydoux, Emilie ;

Jennewein, Madeleine F. ;

MacCamy, Anna J. ;

Feng, Junli ;

Mize, Gregory ;

De Rosa, Stephen C. ;

Finzi, Andres ;

Lemos, Maria P. ;

Cohen, Kristen W. ;

Moodie, Zoe ;

McElrath, M. Juliana ;

McGuire, Andrew T. .

SCIENCE, 2021, 372 (6549) :1413-+

[45] Node-Splitting Generalized Linear Mixed Models for Evaluation of Inconsistency in Network Meta-Analysis [J].

Tu, Yu-Kang .

VALUE IN HEALTH, 2016, 19 (08) :957-963

[46] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [J].

Voysey, Merryn ;

Clemens, Sue Ann Costa ;

Madhi, Shabir A. ;

Weckx, Lily Y. ;

Folegatti, Pedro M. ;

Aley, Parvinder K. ;

Angus, Brian ;

Baillie, Vicky L. ;

Barnabas, Shaun L. ;

Bhorat, Qasim E. ;

Bibi, Sagida ;

Briner, Carmen ;

Cicconi, Paola ;

Clutterbuck, Elizabeth A. ;

Collins, Andrea M. ;

Cutland, Clare L. ;

Darton, Thomas C. ;

Dheda, Keertan ;

Dold, Christina ;

Duncan, Christopher J. A. ;

Emary, Katherine R. W. ;

Ewer, Katie J. ;

Flaxman, Amy ;

Fairlie, Lee ;

Faust, Saul N. ;

Feng, Shuo ;

Ferreira, Daniela M. ;

Finn, Adam ;

Galiza, Eva ;

Goodman, Anna L. ;

Green, Catherine M. ;

Green, Christopher A. ;

Greenland, Melanie ;

Hill, Catherine ;

Hill, Helen C. ;

Hirsch, Ian ;

Izu, Alane ;

Jenkin, Daniel ;

Joe, Carina C. D. ;

Kerridge, Simon ;

Koen, Anthonet ;

Kwatra, Gaurav ;

Lazarus, Rajeka ;

Libri, Vincenzo ;

Lillie, Patrick J. ;

Marchevsky, Natalie G. ;

Marshall, Richard P. ;

Mendes, Ana V. A. ;

Milan, Eveline P. ;

Minassian, Angela M. .

LANCET, 2021, 397 (10277) :881-891

[47]

Wells G., 2000, The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomised studies in meta-analyses

[48]

WHO, 2021, COR DIS COVID19 VACC

[49] The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19 [J].

Ye, Qing ;

Wang, Bili ;

Mao, Jianhua .

JOURNAL OF INFECTION, 2020, 80 (06) :607-613

← 1 2 3 4 5 →